Inhibikase Therapeutics Q2 EPS $(0.11), Inline
Inhibikase Therapeutics (NASDAQ: IKT ) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate. This is unchanged from the same period last year.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.